Biotech Values

[mcbio]

Luke Timmerman writes on ONTY’s ‘Son of Stimuvax’, ONT-10

I'm not willing to gamble on ONTY finding success with Stimuvax in Phase 3 but, if it does indeed fail and the stock gets crushed, ONTY might be worth a look given ONT-10. (I'd like to see them do another raise before the pivotal Stimuvax results are released just so they are in decent financial shape at that time and have some leverage with ONT-10.)